pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
BioPharma Dive·2h ago·1 min read
save

Medicare Part D premiums expected to rise 50% on average in 2027, KFF warns seniors to compare plans

Nov 3, 2026·read at BioPharma Dive ↗RegulatoryNegative

KFF analysis shows average monthly premiums for Medicare Part D standalone plans will jump from $34 to $51 in 2027, a 50% increase if seniors stay in their current plans.

Premiums vary widely across carriers, ranging from $6 to $204 per month, underscoring the need for careful plan comparison.

Roughly 25 million seniors rely on standalone Part D coverage, and about 10.4 million who do not qualify for financial assistance will face higher costs.

The rise follows the termination of a Trump‑era program that limited premium hikes, and open enrollment runs through Dec 7, giving seniors a chance to switch to cheaper options.

source

This writeup was produced by pharmadog from original reporting by BioPharma Dive.

Original headline: “Medicare Part D premiums are spiking 50% on average next year, KFF finds”

read at BioPharma Dive ↗
889 words · retrieved 1h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 2h agoUniQure gets an FDA decision date; Teva scraps brain drug studyBioPharma Dive
  • 23h agoKaryopharm, deep in debt, to sell itself in bankruptcyBioPharma Dive
  • 1d agoKeytruda biosimilars are coming — but they face an uphill battleBioPharma Dive
  • 1d agoEarnings roundup: AstraZeneca’s cost cuts, Alnylam’s slump and Regeneron’s resilienceBioPharma Dive
  • 1d agoBreaking the silos: What effective scenario modeling looks like in 2026 and beyondBioPharma Dive